

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): January 20, 2026**

**SeaStar Medical Holding Corporation**

**(Exact name of Registrant as Specified in Its Charter)**

|  |   |  |
|--|---|--|
| <b>Delaware</b><br><b>(State or Other Jurisdiction</b>                     | <b>001-39927</b><br><b>(Commission File Number)</b> | <b>85-3681132</b><br><b>(IRS Employer</b>            |
| <b>of Incorporation)</b><br><b>3513 Brighton Blvd,</b><br><b>Suite 410</b> |   | <b>Identification</b>                                |
| <b>Denver, Colorado</b><br><b>(Address of Principal Executive Offices)</b> |   | <b>No.)</b><br><br><b>80216</b><br><b>(Zip Code)</b> |

**Registrant's Telephone Number, Including Area Code: 844 427-8100**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

| <b>Title of each class</b>  | <b>Trading<br/>Symbol(s)</b> | <b>Name of each exchange on which registered</b> |
|---|------------------------------|--|
| Common Stock par value \$0.0001 per share   | ICU                          | The Nasdaq Stock Market LLC                      |
| Warrants, each whole warrant exercisable for one share of<br>Common Stock for \$11.50 per share | ICUCW                        | The Nasdaq Stock Market LLC                      |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01. Other Events**

*Regaining Compliance with the \$1.00 Bid Price Rule*

On January 20, 2026, the Company received a letter from the Nasdaq Office of General Counsel confirming that the Company has regained compliance with the minimum bid price requirement of the Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Rule").

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 20, 2026

By:  
Name:  
Title:

SeaStar Medical Holding Corporation  
/s/ Eric Schlorff  
Eric Schlorff  
\_\_\_\_\_  
Chief Executive Officer

---